Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-01-2020 | NSCLC | Review – Clinical Oncology

Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases

Authors: Wang Li, Hong Yu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2020

Abstract

With the advancement of imaging technology, systemic disease control rate and survival rate, the morbidity of brain metastases (BMs) from non-small cell lung cancer (NSCLC) has been riding on a steady upward trend (40%), but management of BMs from NSCLC remains obscure. Systemic therapy is anticipated to offer novel therapeutic avenues in the management of NSCLC BMs, and radiotherapy (RT) and immunotherapy have their own advantages. Recently, it was confirmed that immune checkpoint inhibitors (ICIs) and RT could mutually promote the efficacy in the treatment of BMs from NSCLC. In this paper, we provide a review on current understandings and practices of separating or combining ICIs and RT, which could provide a reference for the coming laboratory and clinical studies and contribute to the development of new approaches in NSCLC BMs.

Ahmed KA et al (2017) Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol 133:331–338. https://doi.org/10.1007/s11060-017-2437-5 CrossRefPubMed

Aldarouish M, Wang C (2016) Trends and advances in tumor immunology and lung cancer immunotherapy. J Exp Clin Cancer Res 35:157. https://doi.org/10.1186/s13046-016-0439-3 CrossRefPubMedPubMedCentral

Aoyama H et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491. https://doi.org/10.1001/jama.295.21.2483 CrossRefPubMed

Aoyama H, Tago M, Shirato H (2015) Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol 1:457–464. https://doi.org/10.1001/jamaoncol.2015.1145 CrossRefPubMed

Berghoff AS et al (2016) Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 5:e1057388. https://doi.org/10.1080/2162402x.2015.1057388 CrossRefPubMed

Bi WL et al (2019) Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. https://doi.org/10.3322/caac.21552 CrossRefPubMedPubMedCentral

Bjornhart B, Hansen KH, Jorgensen TL, Herrstedt J, Schytte T (2019) Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol (Stockholm, Sweden) 58:953–961. https://doi.org/10.1080/0284186x.2019.1615636 CrossRef

Borgelt B et al (1980) The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1–9CrossRefPubMed

Borghaei H et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643 CrossRefPubMedPubMedCentral

Botticelli A et al (2018) Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J Transl Med 16:219. https://doi.org/10.1186/s12967-018-1595-3 CrossRefPubMedPubMedCentral

Brahmer J et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627 CrossRefPubMedPubMedCentral

Britschgi C, Riesterer O, Burger IA, Guckenberger M, Curioni-Fontecedro A (2018) Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer. Radiat Oncol (London, England) 13:102. https://doi.org/10.1186/s13014-018-1049-3 CrossRef

Brown PD et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316:401–409. https://doi.org/10.1001/jama.2016.9839 CrossRefPubMedPubMedCentral

Chang EL et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044. https://doi.org/10.1016/s1470-2045(09)70263-3 CrossRefPubMed

Chen Y et al (2016) First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma. Cancer Sci 107:1800–1805. https://doi.org/10.1111/cas.13079 CrossRefPubMedPubMedCentral

Chen L et al (2018) Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys 100:916–925. https://doi.org/10.1016/j.ijrobp.2017.11.041 CrossRefPubMed

Christodoulou C et al (2017) Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). J Neurooncol 134:443–451. https://doi.org/10.1007/s11060-017-2548-z CrossRefPubMed

Churilla TM et al (2017a) Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001. Ann Oncol 28:2588–2594. https://doi.org/10.1093/annonc/mdx332 CrossRefPubMedPubMedCentral

Churilla TM et al (2017b) Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases: a secondary analysis of the North Central Cancer Treatment Group N0574 (Alliance) randomized controlled trial. Int J Radiat Oncol Biol Phys 99:1173–1178. https://doi.org/10.1016/j.ijrobp.2017.07.045 CrossRefPubMedPubMedCentral

Collen C et al (2014) Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol 25:1954–1959. https://doi.org/10.1093/annonc/mdu370 CrossRefPubMed

Dagogo-Jack I, Gill CM, Cahill DP, Santagata S, Brastianos PK (2017) Treatment of brain metastases in the modern genomic era. Pharmacol Ther 170:64–72. https://doi.org/10.1016/j.pharmthera.2016.10.011 CrossRefPubMed

Demaria S, Golden EB, Formenti SC (2015) Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1:1325–1332. https://doi.org/10.1001/jamaoncol.2015.2756 CrossRefPubMed

Deng L et al (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig 124:687–695. https://doi.org/10.1172/jci67313 CrossRefPubMedPubMedCentral

Doherty MK et al (2017) Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. Radiother Oncol 123:195–202. https://doi.org/10.1016/j.radonc.2017.03.007 CrossRefPubMed

Doi H et al (2019) Neutrophil-to-lymphocyte ratio predicts survival after whole-brain radiotherapy in non-small cell lung cancer. In vivo (Athens, Greece) 33:195–201. https://doi.org/10.21873/invivo.11459 CrossRef

Dong H et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800. https://doi.org/10.1038/nm730 CrossRefPubMed

Dovedi SJ et al (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74:5458–5468. https://doi.org/10.1158/0008-5472.can-14-1258 CrossRefPubMed

Du S et al (2018) PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol 13:510–520. https://doi.org/10.1016/j.jtho.2017.12.002 CrossRefPubMed

Dudnik E et al (2016) Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer 98:114–117. https://doi.org/10.1016/j.lungcan.2016.05.031 CrossRefPubMed

Freeman GJ et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034CrossRefPubMedPubMedCentral

Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306. https://doi.org/10.1038/nrc3245 CrossRefPubMed

Fuentes R et al (2018) Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis. Cochrane Database Syst Rev 8:CD012086. https://doi.org/10.1002/14651858.cd012086.pub2 CrossRefPubMed

Garon EB et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028. https://doi.org/10.1056/NEJMoa1501824 CrossRefPubMed

Gauvain C et al (2018) Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer 116:62–66. https://doi.org/10.1016/j.lungcan.2017.12.008 CrossRefPubMed

Gerber DE et al (2017) Treatment design and rationale for a randomized trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small-cell lung cancer (RTOG 3505). Clin Lung Cancer 18:333–339. https://doi.org/10.1016/j.cllc.2016.10.009 CrossRefPubMed

Goldberg SB et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17:976–983. https://doi.org/10.1016/s1470-2045(16)30053-5 CrossRefPubMedPubMedCentral

Gondi V et al (2010a) Hippocampal-sparing whole-brain radiotherapy: a “how-to” technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 78:1244–1252. https://doi.org/10.1016/j.ijrobp.2010.01.039 CrossRefPubMedPubMedCentral

Gondi V, Tome WA, Mehta MP (2010b) Why avoid the hippocampus? A comprehensive review. Radiother Oncol 97:370–376. https://doi.org/10.1016/j.radonc.2010.09.013 CrossRefPubMedPubMedCentral

Gondi V et al (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 32:3810–3816. https://doi.org/10.1200/jco.2014.57.2909 CrossRefPubMedPubMedCentral

Halasz LM, Weeks JC, Neville BA, Taback N, Punglia RS (2013) Use of stereotactic radiosurgery for brain metastases from non-small cell lung cancer in the United States. Int J Radiat Oncol Biol Phys 85:e109–e116. https://doi.org/10.1016/j.ijrobp.2012.08.007 CrossRefPubMed

Halasz LM et al (2016) Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. Cancer 122:2091–2100. https://doi.org/10.1002/cncr.30009 CrossRefPubMed

Hartgerink D et al (2018) Stereotactic radiosurgery in the management of patients with brain metastases of non-small cell lung cancer: indications, decision tools and future directions. Front Oncol 8:154. https://doi.org/10.3389/fonc.2018.00154 CrossRefPubMedPubMedCentral

Harth S et al (2013) Estimation of intracranial failure risk following hippocampal-sparing whole brain radiotherapy. Radiother Oncol 109:152–158. https://doi.org/10.1016/j.radonc.2013.09.009 CrossRefPubMed

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10. https://doi.org/10.1200/jco.1995.13.1.8 CrossRefPubMed

Hellmann MD et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18:31–41. https://doi.org/10.1016/s1470-2045(16)30624-6 CrossRefPubMed

Hirsch FR et al (2017) Lung cancer: current therapies and new targeted treatments. Lancet (London, England) 389:299–311. https://doi.org/10.1016/s0140-6736(16)30958-8 CrossRef

Hodi FS (2007) Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 13:5238–5242. https://doi.org/10.1158/1078-0432.ccr-07-0813 CrossRefPubMed

Hubbeling HG et al (2018) Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer. J Thorac Oncol 13:550–558. https://doi.org/10.1016/j.jtho.2018.01.012 CrossRefPubMed

Iyengar P, Gerber DE (2013) Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J (Sudbury, Mass.) 19:247–262. https://doi.org/10.1097/ppo.0b013e318292e51a CrossRef

Jackman D et al (2010) Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28:357–360. https://doi.org/10.1200/jco.2009.24.7049 CrossRefPubMed

Jiang T et al (2016) Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med 5:1055–1065. https://doi.org/10.1002/cam4.673 CrossRefPubMedPubMedCentral

Johung KL et al (2016) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34:123–129. https://doi.org/10.1200/jco.2015.62.0138 CrossRefPubMed

Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB (2017) Radiosurgery for brain metastases: changing practice patterns and disparities in the United States. J Natl Compr Cancer Netw 15:1494–1502. https://doi.org/10.6004/jnccn.2017.7003 CrossRef

Keller A et al (2017) Hypofractionated stereotactic radiation therapy to the resection bed for intracranial metastases. Int J Radiat Oncol Biol Phys 99:1179–1189. https://doi.org/10.1016/j.ijrobp.2017.08.014 CrossRefPubMed

Khan M et al (2019) Whole brain radiation therapy plus stereotactic radiosurgery in the treatment of brain metastases leading to improved survival in patients with favorable prognostic factors. Front Oncol 9:205. https://doi.org/10.3389/fonc.2019.00205 CrossRefPubMedPubMedCentral

Khuntia D, Brown P, Li J, Mehta MP (2006) Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24:1295–1304. https://doi.org/10.1200/jco.2005.04.6185 CrossRefPubMed

Kiess AP et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368–375. https://doi.org/10.1016/j.ijrobp.2015.01.004 CrossRefPubMedPubMedCentral

Ko EC, Raben D, Formenti SC (2018) The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer. Clin Cancer Res 24:5792–5806. https://doi.org/10.1158/1078-0432.ccr-17-3620 CrossRefPubMed

Kocher M et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134–141. https://doi.org/10.1200/jco.2010.30.1655 CrossRefPubMed

Langer CJ, Mehta MP (2005) Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23:6207–6219. https://doi.org/10.1200/jco.2005.03.145 CrossRefPubMed

Laubli H et al (2017) Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. J Immunother Cancer 5:46. https://doi.org/10.1186/s40425-017-0249-y CrossRefPubMedPubMedCentral

Lesueur P et al (2018) Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: a multicentric retrospective study from the GFPC. Cancer Med 7:5505–5513. https://doi.org/10.1002/cam4.1825 CrossRefPubMedPubMedCentral

Levy A et al (2013) Radiation therapy and immunotherapy: implications for a combined cancer treatment. Crit Rev Oncol/Hematol 85:278–287. https://doi.org/10.1016/j.critrevonc.2012.09.001 CrossRef

Levy A, Massard C, Soria JC, Deutsch E (2016) Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1/2 trial. Eur J Cancer 68:156–162. https://doi.org/10.1016/j.ejca.2016.09.013 CrossRefPubMed

Levy A et al (2018) Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. Eur J Cancer 93:37–46. https://doi.org/10.1016/j.ejca.2018.01.067 CrossRefPubMed

Li YS et al (2016) Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 11:1962–1969. https://doi.org/10.1016/j.jtho.2016.06.029 CrossRefPubMed

Liao BC, Lin CC, Yang JC (2018) Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Expert Opin Pharmacother 19:851–864. https://doi.org/10.1080/14656566.2018.1472765 CrossRefPubMed

Linskey ME et al (2010) The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:45–68. https://doi.org/10.1007/s11060-009-0073-4 CrossRefPubMed

Ma TM et al (2017) A prospective evaluation of hippocampal radiation dose volume effects and memory deficits following cranial irradiation. Radiother Oncol 125:234–240. https://doi.org/10.1016/j.radonc.2017.09.035 CrossRefPubMed

Maemondo M et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388. https://doi.org/10.1056/NEJMoa0909530 CrossRefPubMed

Magnuson WJ et al (2016) Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases. Int J Radiat Oncol Biol Phys 95:673–679. https://doi.org/10.1016/j.ijrobp.2016.01.037 CrossRefPubMed

Magnuson WJ et al (2017) Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol 35:1070–1077. https://doi.org/10.1200/jco.2016.69.7144 CrossRefPubMed

Mak KS et al (2015) Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro-oncology 17:296–302. https://doi.org/10.1093/neuonc/nou146 CrossRefPubMed

Mansfield AS et al (2016) Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 27:1953–1958. https://doi.org/10.1093/annonc/mdw289 CrossRefPubMedPubMedCentral

Mansfield AS et al (2018) Contraction of T cell richness in lung cancer brain metastases. Sci Rep 8:2171. https://doi.org/10.1038/s41598-018-20622-8 CrossRefPubMedPubMedCentral

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. https://doi.org/10.1038/nature07205 CrossRefPubMed

Marchetti M et al (2019) Multisession radiosurgery for perioptic meningiomas: medium-to-long term results from a CyberKnife cooperative study. J Neurooncol 143:597–604. https://doi.org/10.1007/s11060-019-03196-x CrossRefPubMed

Martin AM et al (2018) Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation. JAMA Oncol 4:1123–1124. https://doi.org/10.1001/jamaoncol.2017.3993 CrossRefPubMedPubMedCentral

Martinez P, Mak RH, Oxnard GR (2017) Targeted therapy as an alternative to whole-brain radiotherapy in EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases. JAMA Oncol 3:1274–1275. https://doi.org/10.1001/jamaoncol.2017.1047 CrossRefPubMed

Mehta MP et al (2002) Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445–3453. https://doi.org/10.1200/jco.2002.07.500 CrossRefPubMed

Mehta MP et al (2003) Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21:2529–2536. https://doi.org/10.1200/jco.2003.12.122 CrossRefPubMed

Minniti G et al (2016) Single-fraction versus multifraction (3 × 9 Gy) stereotactic radiosurgery for large (> 2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol Biol Phys 95:1142–1148. https://doi.org/10.1016/j.ijrobp.2016.03.013 CrossRefPubMed

Minniti G et al (2019) Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC). Lung Cancer (Amsterdam, Netherlands) 132:119–125. https://doi.org/10.1016/j.lungcan.2019.04.021 CrossRef

Mulvenna P et al (2016) Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet (London, England) 388:2004–2014. https://doi.org/10.1016/s0140-6736(16)30825-x CrossRef

Niibe Y et al (2016) Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects. BMC Cancer 16:659. https://doi.org/10.1186/s12885-016-2680-8 CrossRefPubMedPubMedCentral

Otake S, Goto T (2019) Stereotactic radiotherapy for oligometastasis. Cancers. https://doi.org/10.3390/cancers11020133 CrossRefPubMedPubMedCentral

Ou SH, Klempner SJ, Azada MC, Rausei-Mills V, Duma C (2015) Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for disease assessment and management. Lung Cancer 88:355–359. https://doi.org/10.1016/j.lungcan.2015.03.022 CrossRefPubMed

Ozdemir Y, Yildirim BA, Topkan E (2016) Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors. J Neurooncol 129:329–335. https://doi.org/10.1007/s11060-016-2179-9 CrossRefPubMed

Passariello M et al (2019) Novel human anti-PD-L1 mAbs inhibit immune-independent tumor cell growth and PD-L1 associated intracellular signalling. Sci Rep 9:13125. https://doi.org/10.1038/s41598-019-49485-3 CrossRefPubMedPubMedCentral

Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29:533–540CrossRefPubMed

Pentcheva-Hoang T, Corse E, Allison JP (2009) Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 229:67–87. https://doi.org/10.1111/j.1600-065X.2009.00763.x CrossRefPubMed

Pike LRG et al (2017) Radiation and PD-1 inhibition: favorable outcomes after brain-directed radiation. Radiother Oncol 124:98–103. https://doi.org/10.1016/j.radonc.2017.06.006 CrossRefPubMed

Prabhu RS et al (2017) Single-fraction stereotactic radiosurgery (SRS) alone versus surgical resection and SRS for large brain metastases: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 99:459–467. https://doi.org/10.1016/j.ijrobp.2017.04.006 CrossRefPubMed

Prabhu RS et al (2018) Preoperative stereotactic radiosurgery before planned resection of brain metastases: updated analysis of efficacy and toxicity of a novel treatment paradigm. J Neurosurg. https://doi.org/10.3171/2018.7.jns181293 CrossRefPubMed

Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–1437. https://doi.org/10.1038/nm.3394 CrossRefPubMedPubMedCentral

Quail DF, Joyce JA (2017) The microenvironmental landscape of brain tumors. Cancer Cell 31:326–341. https://doi.org/10.1016/j.ccell.2017.02.009 CrossRefPubMedPubMedCentral

Rajakesari S et al (2014) Local control after fractionated stereotactic radiation therapy for brain metastases. J Neurooncol 120:339–346. https://doi.org/10.1007/s11060-014-1556-5 CrossRefPubMed

Sacher AG, Gandhi L (2016) Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol 2:1217–1222. https://doi.org/10.1001/jamaoncol.2016.0639 CrossRefPubMed

Salama AK, Hodi FS (2011) Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 17:4622–4628. https://doi.org/10.1158/1078-0432.ccr-10-2232 CrossRefPubMed

Serizawa T et al (2019) Local tumor progression treated with Gamma Knife radiosurgery: differences between patients with 2–4 versus 5–10 brain metastases based on an update of a multi-institutional prospective observational study (JLGK0901). J Neurosurg. https://doi.org/10.3171/2019.1.jns183085 CrossRefPubMed

Shaverdian N et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:895–903. https://doi.org/10.1016/s1470-2045(17)30380-7 CrossRefPubMedPubMedCentral

Shepard MJ et al (2019) Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. J Neurosurg. https://doi.org/10.3171/2019.4.jns19822 CrossRefPubMed

Shien K, Papadimitrakopoulou VA, Wistuba II (2016) Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer 99:79–87. https://doi.org/10.1016/j.lungcan.2016.06.016 CrossRefPubMed

Shukuya T et al (2011) Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer 74:457–461. https://doi.org/10.1016/j.lungcan.2011.04.007 CrossRefPubMed

Shuryak I, Carlson DJ, Brown JM, Brenner DJ (2015) High-dose and fractionation effects in stereotactic radiation therapy: analysis of tumor control data from 2965 patients. Radiother Oncol 115:327–334. https://doi.org/10.1016/j.radonc.2015.05.013 CrossRefPubMed

Shuto T et al (2018) Multiinstitutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases from non-small cell lung cancer (JLGK0901 study-NSCLC). J Neurosurg 129:86–94. https://doi.org/10.3171/2018.7.gks181378 CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Soon YY, Leong CN, Koh WY, Tham IW (2015) EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Radiother Oncol 114:167–172. https://doi.org/10.1016/j.radonc.2014.12.011 CrossRefPubMed

Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I (2013) The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 85:293–295. https://doi.org/10.1016/j.ijrobp.2012.03.017 CrossRefPubMed

Svokos KA, Salhia B, Toms SA (2014) Molecular biology of brain metastasis. Int J Mol Sci 15:9519–9530. https://doi.org/10.3390/ijms15069519 CrossRefPubMedPubMedCentral

Swanton C, Govindan R (2016) Clinical implications of genomic discoveries in lung cancer. N Engl J Med 374:1864–1873. https://doi.org/10.1056/NEJMra1504688 CrossRefPubMed

Takamori S et al (2017) Discrepancy in programmed cell death-ligand 1 between primary and metastatic non-small cell lung cancer. Anticancer Res 37:4223–4228. https://doi.org/10.21873/anticanres.11813 CrossRefPubMed

Tang C et al (2017) Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res 23:1388–1396. https://doi.org/10.1158/1078-0432.ccr-16-1432 CrossRefPubMed

Teglasi V et al (2017) Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. Neuro-oncology 19:1058–1067. https://doi.org/10.1093/neuonc/now309 CrossRefPubMedPubMedCentral

Tran TT et al (2019) Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy. J Immunother Cancer 7:200. https://doi.org/10.1186/s40425-019-0684-z CrossRefPubMedPubMedCentral

Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 10:1240–1242. https://doi.org/10.1097/jto.0000000000000663 CrossRefPubMed

Ulahannan D, Khalifa J, Faivre-Finn C, Lee SM (2017) Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead. Ann Oncol 28:2923–2931. https://doi.org/10.1093/annonc/mdx481 CrossRefPubMed

Vecht CJ et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583–590. https://doi.org/10.1002/ana.410330605 CrossRefPubMed

Vogelbaum MA et al (2006) Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg 104:907–912. https://doi.org/10.3171/jns.2006.104.6.907 CrossRefPubMed

Wang X, Xu Y, Tang W, Liu L (2018a) Efficacy and safety of radiotherapy plus EGFR-TKIs in NSCLC patients with brain metastases: a meta-analysis of published data. Transl Oncol 11:1119–1127. https://doi.org/10.1016/j.tranon.2018.07.003 CrossRefPubMedPubMedCentral

Wang C, Lu X, Lyu Z, Bi N, Wang L (2018b) Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: a meta-analysis. Lung Cancer 122:94–99. https://doi.org/10.1016/j.lungcan.2018.05.014 CrossRefPubMed

Wang Y et al (2018c) Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment. Clin Transl Oncol 20:366–373. https://doi.org/10.1007/s12094-017-1723-1 CrossRefPubMed

Wang Y et al (2019) New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-019-04500-7 CrossRefPubMedPubMedCentral

Xu Q et al (2018) Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol 13:1383–1392. https://doi.org/10.1016/j.jtho.2018.05.019 CrossRefPubMed

Yamamoto M et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2–9 versus 10 or more tumors. J Neurosurg 121(Suppl):16–25. https://doi.org/10.3171/2014.8.gks141421 CrossRefPubMed

Yang JJ et al (2017) Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet 5:707–716. https://doi.org/10.1016/s2213-2600(17)30262-x CrossRef

Yang WC et al (2018) Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol 126:368–374. https://doi.org/10.1016/j.radonc.2017.10.010 CrossRefPubMed

Yi M et al (2018) Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer 17:129. https://doi.org/10.1186/s12943-018-0864-3 CrossRefPubMedPubMedCentral

Zhu Q et al (2017) Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC). Oncotarget 8:13304–13311. https://doi.org/10.18632/oncotarget.14515 CrossRefPubMedPubMedCentral

Zhuang Y et al (2018) PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models. J Cancer Res Clin Oncol 144:1909–1920. https://doi.org/10.1007/s00432-018-2723-4 CrossRefPubMed

Zindler JD et al (2017) Whole brain radiotherapy versus stereotactic radiosurgery for 4–10 brain metastases: a phase III randomised multicentre trial. BMC Cancer 17:500. https://doi.org/10.1186/s12885-017-3494-z CrossRefPubMedPubMedCentral

Title: Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases
Authors: Wang Li
Hong Yu
Publication date: 01-01-2020
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
Metastasis
NSCLC
Radiotherapy
Checkpoint Inhibitors
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-03094-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics

Candidate lncRNA–miRNA–mRNA network in predicting hepatocarcinogenesis with cirrhosis: an integrated bioinformatics analysis

High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1

High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients with locally advanced rectal cancer

The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients

Effects of single-nucleotide polymorphisms in the mTORC1 pathway on the risk of brain metastasis in patients with non-small cell lung cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page